[go: up one dir, main page]

ES2080796T3 - Formulaciones de productos farmaceuticos de liberacion prolongada. - Google Patents

Formulaciones de productos farmaceuticos de liberacion prolongada.

Info

Publication number
ES2080796T3
ES2080796T3 ES90304860T ES90304860T ES2080796T3 ES 2080796 T3 ES2080796 T3 ES 2080796T3 ES 90304860 T ES90304860 T ES 90304860T ES 90304860 T ES90304860 T ES 90304860T ES 2080796 T3 ES2080796 T3 ES 2080796T3
Authority
ES
Spain
Prior art keywords
formulations
pharmaceutical products
prolonged release
coated
release particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90304860T
Other languages
English (en)
Other versions
ES2080796T5 (es
Inventor
George N Paradissis
James A Garegnani
Roy S Whaley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kv Pharmaceutical Co
Original Assignee
Kv Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26996237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2080796(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/349,533 external-priority patent/US5122384A/en
Application filed by Kv Pharmaceutical Co filed Critical Kv Pharmaceutical Co
Publication of ES2080796T3 publication Critical patent/ES2080796T3/es
Application granted granted Critical
Publication of ES2080796T5 publication Critical patent/ES2080796T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA FORMULACION FARMACEUTICA DE REPOSICION EXTENDIDA SE ADAPTA PAA APROXIMARSE AL ORDEN CERO DE REPOSICION DE UNA DROGA SOBRE UN PERIODO DE 12 A 24 HORAS, Y COMPRENDE UNA MEZCLA DE 0 A 50% DE UNA PARTICULA DE REPOSICION INMEDIATA QUE CONTIENE UNA DROGA, UN SUSTRATO INERTE Y UN ENLACE REVESTIDO CON TALCO; Y HASTA EL 100% DE UNA PARTICULA DE REPOSICION EXTENDIDA QUE COMPRENDE UNA PARTICULA DE EVACUACION INMEDIATA, REVESTIDA CON UN SISTEMA MODIFICADOR DE DISOLUCIONES QUE CONTIENE PLASTICIDAS Y UN AGENTE MOLDEADOR DE PELICULAS.
ES90304860T 1989-05-05 1990-05-04 Formulaciones de productos farmaceuticos de liberacion prolongada. Expired - Lifetime ES2080796T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/349,533 US5122384A (en) 1989-05-05 1989-05-05 Oral once-per-day organic nitrate formulation which does not induce tolerance
US07/469,210 US5133974A (en) 1989-05-05 1990-01-24 Extended release pharmaceutical formulations

Publications (2)

Publication Number Publication Date
ES2080796T3 true ES2080796T3 (es) 1996-02-16
ES2080796T5 ES2080796T5 (es) 1999-05-16

Family

ID=26996237

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90304860T Expired - Lifetime ES2080796T5 (es) 1989-05-05 1990-05-04 Formulaciones de productos farmaceuticos de liberacion prolongada.

Country Status (7)

Country Link
US (2) US5133974A (es)
EP (1) EP0396425B2 (es)
AT (1) ATE128863T1 (es)
AU (1) AU635021B2 (es)
CA (1) CA2016039C (es)
DE (1) DE69022876T3 (es)
ES (1) ES2080796T5 (es)

Families Citing this family (647)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
ES2064564T3 (es) * 1989-09-21 1995-02-01 American Cyanamid Co Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina.
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
IT1252185B (it) * 1991-12-11 1995-06-05 Therapicon Srl Preparazioni farmaceutiche a liberazione programmata
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
EP0550108B1 (en) * 1991-12-30 1998-03-18 Akzo Nobel N.V. Sustained release thyroactive composition
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
WO1993017673A1 (en) * 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
JPH0733645A (ja) * 1992-05-28 1995-02-03 Elan Corp Plc 錠剤製剤
CA2141435A1 (en) * 1992-07-30 1994-02-17 William Byrne Ester of an organic nitrate and a salicylate
US5422122A (en) * 1992-08-04 1995-06-06 Eurand America, Incorporated Controlled release potassium chloride tablet
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
EP0711166A1 (en) * 1993-07-22 1996-05-15 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
JP2716361B2 (ja) * 1994-02-16 1998-02-18 株式会社アドバンス 生体用プリント電極
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US7060293B1 (en) 1994-05-25 2006-06-13 Purdue Pharma Powder-layered oral dosage forms
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
GB9503492D0 (en) * 1995-02-22 1995-04-12 Ed Geistlich S Hne A G F R Che Chemical product
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
WO1997000674A1 (en) * 1995-06-20 1997-01-09 Pharma-Vinci A/S A method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
RU2161481C2 (ru) * 1995-09-21 2001-01-10 Фарма Пасс Ллс Новая композиция, содержащая кислотно-нестойкий омепразол, и способ ее получения
DE69631981T2 (de) 1995-09-21 2005-04-14 Pharma Pass Ii Llc, Irvine Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US20060062843A1 (en) * 1996-03-25 2006-03-23 Wyeth Extended release formulation
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
DE69739165D1 (de) 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
IT1283478B1 (it) * 1996-07-22 1998-04-21 Roberto Valducci Composizioni per integrazione nutrizionale comprendenti vitamine idrosolubili a rilascio prolungato
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
WO1998029095A2 (en) * 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
FR2760190B1 (fr) * 1997-02-28 1999-04-09 Adir Composition pharmaceutique pour la liberation programmee de dexfenfluramine
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
ES2263211T3 (es) 1997-07-02 2006-12-01 Euro-Celtique S.A. Formulaciones de tramadol de liberacion sostenida estabilizada.
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
FR2774910B1 (fr) * 1998-02-16 2001-09-07 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US6197347B1 (en) 1998-06-29 2001-03-06 Andrx Pharmaceuticals, Inc. Oral dosage for the controlled release of analgesic
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6368625B1 (en) * 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6126967A (en) * 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US6254891B1 (en) * 1998-09-03 2001-07-03 Ascent Pediatrics, Inc. Extended release acetaminophen
JP2000109341A (ja) * 1998-10-01 2000-04-18 Jsr Corp 無機粒子含有組成物、転写フィルムおよびプラズマディスプレイパネルの製造方法
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
CA2347104A1 (en) * 1998-10-26 2000-04-05 Tanabe Seiyaku Co., Ltd. Sustained-release particles
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
CA2348871C (en) 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
CA2351347A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
CN100370990C (zh) * 1998-12-24 2008-02-27 詹森药业有限公司 控释加兰他敏组合物
AU776672B2 (en) 1998-12-30 2004-09-16 Beth Israel Deaconess Medical Center Characterization of a calcium channel family
US6274162B1 (en) 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
ATE449754T1 (de) 1999-05-14 2009-12-15 Nereus Pharmaceuticals Inc Interleukin-1 und tumornekrosefaktor-alpha modulatoren,synthese dieser modulatoren und methoden zur anwendung dieser modulatoren
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
FR2794646B1 (fr) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
ES2592507T3 (es) 1999-09-03 2016-11-30 The Brigham And Women's Hospital, Inc. Métodos y composiciones para el tratamiento de enfermedad inflamatoria mediante el uso de agentes moduladores de cadherina-11
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
CN100391438C (zh) * 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
HK1042427A1 (zh) * 1999-09-30 2002-08-16 Penwest Pharmaceuticals Co. 用於高溶度药物的持续释放基质方法
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
CA2400642A1 (en) * 2000-02-23 2001-08-30 Vertex Pharmaceuticals (San Diego) Llc Modified fluorescent proteins
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6623758B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AU3984101A (en) * 2000-02-24 2001-09-03 Advanced Pharma Inc Antibiotic and antifungal compositions
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
JP2003530432A (ja) * 2000-04-12 2003-10-14 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患の治療
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
CA2410371C (en) 2000-06-22 2015-11-17 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
DE10033023A1 (de) * 2000-07-07 2002-01-31 Biogrund Gmbh Filmüberzugszusammensetzung auf Basis von Zellulosederivaten und Zuckeralkoholen
US6855721B1 (en) 2000-07-28 2005-02-15 Indevus Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
CA2417930A1 (en) * 2000-08-10 2002-02-14 Unihart Corporation Pharmaceutical compositions containing lithium carbonate
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
BR0115382A (pt) 2000-10-30 2003-09-16 Euro Celtique Sa Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
WO2002047610A2 (en) * 2000-11-16 2002-06-20 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product dicovery
CA2430060C (en) 2000-11-27 2015-11-24 Minerva Biotechnologies Corporation Identification and use of cell surface receptor-binding ligands for the diagnosis and treatment of cancer
DE60134421D1 (de) * 2000-12-08 2008-07-24 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
US6706274B2 (en) * 2001-01-18 2004-03-16 Scimed Life Systems, Inc. Differential delivery of nitric oxide
ITMI20010220A1 (it) * 2001-02-05 2002-08-05 Valpharma Sa Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20030190360A1 (en) * 2001-03-13 2003-10-09 Baichwal Anand R. Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
DE60234183D1 (de) 2001-06-05 2009-12-10 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
NZ552377A (en) 2001-08-17 2008-08-29 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
EP1455593B1 (en) 2001-10-06 2013-07-24 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6780437B2 (en) * 2001-10-23 2004-08-24 Upsher-Smith Laboratories, Inc. Coated potassium chloride granules and tablets
US20030125292A1 (en) * 2001-11-07 2003-07-03 Sean Semple Mucoscal vaccine and methods for using the same
US6821532B2 (en) * 2001-11-16 2004-11-23 Unitel Technologies, Inc. Methods and compositions for the treatment of benign prostatic hypertrophy
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
KR20030056474A (ko) * 2001-12-28 2003-07-04 한국유나이티드제약 주식회사 카르비도파/레보도파 서방정의 조성물과 그의 제조방법
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
ES2543710T3 (es) 2002-04-04 2015-08-21 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimulantes que contienen G y U
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
CA2483028C (en) * 2002-05-06 2011-04-05 Massachusetts Institute Of Technology Diffusion-controlled dosage form and method of fabrication including three dimensional printing
SI2336359T1 (sl) 2002-05-09 2016-08-31 The Brigham And Women's Hospital, Inc. 1L1RL-1 kot marker kardiovaskularne bolezni
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US7176232B2 (en) * 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
WO2004002565A1 (en) * 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
CN1671400A (zh) * 2002-07-03 2005-09-21 派瑞克科学公司 透明质酸组合物以及使用方法
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
PE20040134A1 (es) * 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
AU2003272601B2 (en) * 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
US7112581B2 (en) * 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20030049698A1 (en) * 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
DK2241325T3 (da) 2002-10-29 2012-04-10 Coley Pharm Group Inc Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
EP2363410B1 (en) 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation Isoforms of MUC1
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
AU2003293833B2 (en) * 2002-12-12 2009-10-01 Covis Pharma B.V. Combination medicament
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7863287B2 (en) * 2002-12-18 2011-01-04 Wyeth Llc Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2510320C (en) * 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
EP1592786B8 (en) 2003-02-11 2012-03-21 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies using a formylglycine generating enzyme (fge)
EP1599474B1 (en) * 2003-03-04 2013-04-24 California Institute Of Technology Heterocyclic oligomeric compounds for DNA recognition
DE10311585A1 (de) * 2003-03-14 2004-09-23 Basf Ag Wirkstoffhaltige Adsorbate
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
EP1651207A4 (en) 2003-06-12 2008-10-01 Univ Colorado SYSTEMS AND METHODS FOR THE TREATMENT OF HUMAN INFLAMMATORY AND PROLIFERATIVE DISEASES AND INJURIES USING INHIBITORS OF FATTY ACID METABOLISM AND / OR GLYCOLYTIC INHIBITORS
AU2004253478A1 (en) * 2003-06-20 2005-01-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
US8217072B2 (en) * 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US8425936B2 (en) 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005016317A1 (en) * 2003-08-19 2005-02-24 Themis Laboratories Private Limited Process for manufacture of extended release pellets containing diltiazem hci
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
EP1670442A4 (en) * 2003-09-19 2011-09-14 Penwest Pharmaceuticals Co DOSAGE FORMS WITH DELAYED RELEASE
MXPA06003101A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
WO2005034979A2 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005044199A2 (en) * 2003-11-05 2005-05-19 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005060610A2 (en) * 2003-12-11 2005-07-07 The Trustees Of Columbia University In The City Ofnew York Nano-sized particles, processes of making, compositions and uses thereof
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
EP2248895B8 (en) 2003-12-19 2016-09-21 Autotelic LLC Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
US7452730B2 (en) * 2004-01-16 2008-11-18 California Institute Of Technology DNA-binding polymers
AU2005206560A1 (en) * 2004-01-23 2005-08-04 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobials agents
JP2007524698A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
EP1722823A2 (en) * 2004-02-27 2006-11-22 Antisense Pharma GmbH Pharmaceutical composition
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US7491263B2 (en) 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
JP2007533706A (ja) * 2004-04-20 2007-11-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用
CA2567748A1 (en) 2004-04-21 2005-11-03 The Brigham And Women's Hospital, Inc. Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
MXPA06012564A (es) * 2004-04-27 2007-01-31 Medicinova Inc Derivados de acido fenoxialquilcarboxilico en el tratamiento de enfermedades inflamatorias.
US7276530B2 (en) 2004-04-30 2007-10-02 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
RU2382637C2 (ru) * 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
AU2005244401B2 (en) * 2004-05-14 2009-01-22 Green Cross Corp. Neuroprotective properties of dextrorotatory morphinans
MX339690B (es) * 2004-06-04 2016-06-06 Xenoport Inc Profarmacos de levodopa y sus composiciones y usos.
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
PT1781260E (pt) * 2004-08-13 2010-12-20 Boehringer Ingelheim Int Formulação em comprimido de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável, um método para a preparação do mesmo e sua utilização
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CA2583375C (en) 2004-09-02 2013-01-15 Yale University Regulation of oncogenes by micrornas
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
JP5635726B2 (ja) * 2004-09-14 2014-12-03 ミネルバ バイオテクノロジーズ コーポレーション 癌の診断方法及び治療方法
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
AU2005304687B2 (en) 2004-11-11 2012-01-19 The General Hosptial Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
EP1830838B1 (en) * 2004-12-03 2012-10-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplastic diseases
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
AU2005313887B2 (en) * 2004-12-09 2011-10-27 Celgene Corporation Treatment using D-threo methylphenidate
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
US20090123536A1 (en) * 2005-02-21 2009-05-14 Flamel Technologies, S.A. Oral Pharmaceutical Form of Losartan
FR2882259A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
JP2008543276A (ja) 2005-03-30 2008-12-04 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１発現細胞の増殖
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
BRPI0608917A2 (pt) * 2005-04-12 2017-07-11 Elan Pharma Int Ltd Composição de liberação controlada de antibiótico, e, método para o tratamento de infecção bacteriana
EP1874343A4 (en) 2005-04-19 2009-07-22 Lilly Co Eli MONOVALENT AND MULTIPURPOSE SYNTHETIC POLYSACCHARIDIC ANATIGENS FOR IMMUNOLOGICAL INTERVENTION IN PATHOLOGY
CA2609788A1 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
RU2427377C2 (ru) 2005-05-05 2011-08-27 Антисенс Фарма Гмбх Дозирование олигонуклеотидов
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
PT1899378E (pt) 2005-06-21 2010-01-26 Xoma Technology Ltd Anticorpos de ligação de il-1β e os seus fragmentos
WO2007002528A1 (en) * 2005-06-23 2007-01-04 Yale University Anti-aging micrornas
US20080299204A1 (en) * 2005-06-23 2008-12-04 Spherics, Inc. Dosage forms for movement disorder treatment
US7893299B2 (en) 2005-07-21 2011-02-22 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-αmodulators; syntheses of such modulators and methods of using such modulators
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
RU2008113439A (ru) * 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
CN101252932B (zh) * 2005-09-09 2012-10-03 安吉利尼莱博法姆有限责任公司 用于一天给药一次的曲唑酮组合物
US20070098791A1 (en) * 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
US20070098796A1 (en) 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
EP1959966B1 (en) * 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
RU2429223C2 (ru) 2005-12-05 2011-09-20 Ксенопорт, Инк. Мезилатное пролекарство леводопы, его композиции и применение
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
RU2465263C2 (ru) * 2006-04-28 2012-10-27 Грюненталь Гмбх Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и нестероидный противовоспалительный препарат
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
TWI405567B (zh) * 2006-06-01 2013-08-21 Merck Sharp & Dohme 持續釋放脫羥腎上腺素之醫藥組合物
TW200808376A (en) * 2006-06-01 2008-02-16 Schering Corp Phenylephrine pulsed release formulations and pharmaceutical compositions
CN104161736A (zh) * 2006-06-01 2014-11-26 Msd消费保健品公司 包含去氧肾上腺素的缓释药物制剂
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
AU2007263281B2 (en) 2006-06-20 2012-12-06 Transgene S.A. Recombinant viral vaccine
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2008147426A2 (en) * 2006-10-04 2008-12-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
US20090297626A1 (en) * 2006-11-03 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for preparing metal oxides
WO2008061226A2 (en) 2006-11-17 2008-05-22 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
WO2008064192A2 (en) * 2006-11-21 2008-05-29 Mcneil-Ppc, Inc. Modified release analgesic suspensions
EA201300152A1 (ru) 2006-11-27 2013-07-30 Х. Лундбекк А/С Гетероариламидные производные
EP2101735A2 (en) 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
CA2673336A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US20080152709A1 (en) * 2006-12-22 2008-06-26 Drugtech Corporation Clonidine composition and method of use
WO2008086529A2 (en) * 2007-01-11 2008-07-17 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US20080187579A1 (en) * 2007-02-01 2008-08-07 Pavan Bhat Extended-release dosage form
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
WO2008112388A1 (en) 2007-03-14 2008-09-18 Drugtech Corporation Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
PA8774201A1 (es) 2007-03-29 2009-06-23 Progenics Pharm Inc Antagonista del receptor
ES2466672T3 (es) 2007-04-02 2014-06-10 Theracos, Inc. Derivados de glicósido bencílico y métodos de uso
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
CA2718573C (en) 2007-04-12 2020-07-14 The Brigham And Women's Hospital, Inc. Targeting abcb5 for cancer therapy
WO2008130619A2 (en) * 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
CA2685118C (en) 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CA2687441A1 (en) * 2007-05-17 2008-11-27 Coley Pharmaceutical Group, Inc. Class a oligonucleotides with immunostimulatory potency
BRPI0812784A2 (pt) * 2007-06-01 2014-12-02 Schering Plough Healthcare Composição farmacêutica compreendendo um substrato e um revestimento contendo um ingrediente ativo e polivinilálcool
JP2010529142A (ja) * 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
ES2574836T3 (es) * 2007-06-08 2016-06-22 Boehringer Ingelheim International Gmbh Formulación de liberación prolongada de nevirapina
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
WO2008156676A1 (en) 2007-06-15 2008-12-24 President And Fellows Of Harvard College Methods and compositions for detecting and modulating o-glycosylation
US20100291219A1 (en) * 2007-06-21 2010-11-18 Massachusetts Institute Of Technology Methods and compositions relating to progenitor cells
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
WO2009022215A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
JP4809931B2 (ja) 2007-08-23 2011-11-09 セラコス・インコーポレイテッド ベンジルベンゼン誘導体およびその使用方法
WO2009049160A1 (en) 2007-10-12 2009-04-16 Takeda Pharmaceuticals North America Methods of treating gastrointestinal disorders independent of the intake of food
EP2203166B1 (en) * 2007-10-16 2015-05-06 Paladin Labs Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2219612A4 (en) * 2007-12-17 2013-10-30 Paladin Labs Inc FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION
HRP20141194T1 (hr) 2007-12-20 2015-04-24 Xoma (Us) Llc Postupci lijeäśenja gihta
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009111375A2 (en) * 2008-03-01 2009-09-11 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20110191868A1 (en) 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
WO2009130616A2 (en) 2008-04-25 2009-10-29 Innate Pharma Improved tlr3 agonist compositions
EP2288704A2 (en) * 2008-05-07 2011-03-02 Abraxis BioScience, LLC Enhancement of drug therapy by mirna
WO2009137827A2 (en) * 2008-05-09 2009-11-12 Tiara Pharmaceuticals, Inc. Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
US7910616B2 (en) * 2008-05-12 2011-03-22 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
EP2303888B1 (en) 2008-06-12 2015-05-06 President and Fellows of Harvard College Compounds for antimicrobial intervention
MX2011000637A (es) 2008-07-15 2011-05-02 Theracos Inc Derivados deuretados de bencilbenceno y metodos de uso.
AU2009274512A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
CN102202656A (zh) 2008-08-15 2011-09-28 蒂宝制药公司 治疗和预防cns障碍的胃滞留药用组合物
EP2324002B1 (en) 2008-08-22 2016-10-05 Theracos Sub, LLC Processes for the preparation of sglt2 inhibitors
US20110092493A1 (en) * 2008-09-24 2011-04-21 Clark Levi Dose-controlled transdermal promethazine compositions and methods of use
JP5722782B2 (ja) * 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
EP2452677A1 (en) * 2008-09-29 2012-05-16 Wockhardt Limited Extended release dosage form of ropinirole
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP2012505636A (ja) 2008-10-09 2012-03-08 ミネルバ バイオテクノロジーズ コーポレーション 細胞において多能性を誘導する方法
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010047775A2 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CN104208714A (zh) 2008-11-18 2014-12-17 Ucb医药有限公司 含有2-氧代-1-吡咯烷衍生物的延长释放制剂
JP5930278B2 (ja) 2008-11-25 2016-06-08 ユニバーシティー オブ ロチェスター Ｍｌｋ阻害剤および使用方法
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
WO2010101627A2 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
WO2010127100A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extented release formulations
US20100280059A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
DK2992899T3 (da) 2009-05-14 2020-09-14 Bayer Ip Gmbh Forøget immunrespons hos fuglearter
JP5640079B2 (ja) 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 油滴含有組成物
EP2438046A4 (en) 2009-06-01 2013-04-17 Harvard College O-GLCNAC TRANSFERASE HEMMER AND USES THEREOF
EP3020412B1 (en) 2009-06-16 2017-10-11 The Regents of the University of Michigan An immunogenic composition comprising nanoemulsion inactivated rsv
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2011011092A1 (en) 2009-07-22 2011-01-27 University Of Massachusetts Methods and compositions to reduce oxidative stress
PE20121495A1 (es) 2009-07-30 2012-11-19 Antisense Pharma Gmbh Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
PL2467377T3 (pl) 2009-08-18 2017-10-31 Ventirx Pharmaceuticals Inc Podstawione benzoazepiny jako modulatory receptora toll-podobnego
WO2011022509A2 (en) 2009-08-18 2011-02-24 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
NO2462246T3 (es) 2009-09-28 2018-02-03
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
NZ600256A (en) 2009-12-02 2014-05-30 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
EP3138915A1 (en) 2010-05-04 2017-03-08 The Brigham and Women's Hospital, Inc. Detection and treatment of fibrosis
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
CA2800176C (en) 2010-05-24 2018-08-28 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
LT2654785T (lt) 2010-12-22 2019-07-10 Bayer Intellectual Property Gmbh Sustiprintas galvijų imuninis atsakas
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US9718796B2 (en) 2011-01-12 2017-08-01 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
BR112013017947A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores de receptor toll-like
CN105969773A (zh) 2011-02-03 2016-09-28 米尔纳医疗股份有限公司 Mir-124的合成模拟物
JP2014506791A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−３４の合成模倣体
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP6133790B2 (ja) 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
CA2830503A1 (en) 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
CN103796683A (zh) 2011-04-21 2014-05-14 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
EP2713737B1 (en) 2011-06-01 2016-04-20 Janus Biotherapeutics, Inc. Novel immune system modulators
JP6093759B2 (ja) 2011-06-01 2017-03-08 ジャナス バイオセラピューティクス，インク． 新規の免疫系調節剤
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013013061A1 (en) 2011-07-19 2013-01-24 University Of Vermont And State Agricultural College Methods and compounds for treating cancer
CA2844197A1 (en) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolina Healthcare System Treatment of fibrosis using microrna-19b
US9873694B2 (en) 2011-10-04 2018-01-23 Janus Biotherapeutics, Inc. Imidazole quinoline-based immune system modulators
CA2852244C (en) 2011-10-17 2023-10-17 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
WO2013082275A1 (en) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
US8835499B2 (en) 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
EP2794657B1 (en) 2011-12-19 2017-10-11 Xoma (Us) Llc Methods for treating acne
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
JP6442403B2 (ja) 2012-07-11 2018-12-19 ユニバーシティ・オブ・バーモント・アンド・ステイト・アグリカルチュラル・カレッジＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｖｅｒｍｏｎｔ Ａｎｄ Ｓｔａｔｅ Ａｇｒｉｃｕｌｔｕｒａｌ Ｃｏｌｌｅｇｅ 代謝調節のための方法および組成物
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
US9636376B2 (en) 2012-09-11 2017-05-02 Innopharma, Inc. Stable compositions of peptide epoxy ketones
EP2904119B1 (en) 2012-10-02 2020-06-17 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
WO2014055941A2 (en) 2012-10-04 2014-04-10 Pappalardo Juan Sabastian Compounds and methods for targeted immune system delivery
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
CA2905090C (en) 2013-03-15 2022-10-25 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
SG10201604814WA (en) 2013-03-21 2016-08-30 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
CN111518199A (zh) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105407884B (zh) 2013-07-25 2019-04-30 美迪诺亚公司 降低甘油三酯、总胆固醇和低密度脂蛋白血液浓度的方法
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
KR102357968B1 (ko) 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
BR112016019837A2 (pt) 2014-02-28 2017-10-17 Bayer Animal Health Gmbh plasmídeos imunoestimuladores
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
WO2015170195A1 (en) * 2014-05-03 2015-11-12 GORREPATI, Navaneeta Krishna Hydrazaline hydrochloride pellets and its preparation method
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
WO2015172149A1 (en) 2014-05-09 2015-11-12 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US9498458B2 (en) 2014-06-02 2016-11-22 Medicinova, Inc. Method of inhibiting or treating fibrosis
US20170275287A1 (en) 2014-08-22 2017-09-28 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
JP2017527614A (ja) 2014-09-02 2017-09-21 ブピンダー シン 重水素化又は非重水素化分子及び医薬製剤
DK3193840T3 (da) * 2014-09-15 2021-08-16 Orphazyme As Arimoclomol-formulering
RU2017106028A (ru) 2014-09-19 2018-10-22 Дзе Проктер Энд Гэмбл Компани Лекарственная форма фенилэфрина с пульсирующим высвобождением
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2963923A1 (en) 2014-10-08 2016-04-14 Pacific Northwest Research Institute Methods and compounds for increasing the potency of antifungal agents
JP7158853B2 (ja) 2014-10-10 2022-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物
CN107249327A (zh) 2014-10-17 2017-10-13 萨利克斯药品公司 使用甲基纳曲酮减缓肿瘤进展
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
PT3215127T (pt) 2014-11-07 2021-02-10 Sublimity Therapeutics Ltd Composições que compreendem ciclosporina
CN107108442A (zh) 2014-11-14 2017-08-29 燿石治疗公司 用于制备α,ω‑二羧酸封端的二烷醚的方法和中间体
BR112017010700A2 (pt) 2014-11-26 2018-05-08 Medicinova Inc combinação de ibudilaste e riluzol e métodos de uso da mesma
MA41152A (fr) * 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
US11746159B2 (en) 2015-02-10 2023-09-05 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
CA2977050A1 (en) 2015-02-18 2016-08-25 University Of Vermont And State Agricultural College Mcj agonists and uses therefor
US10647964B2 (en) 2015-03-05 2020-05-12 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016168658A1 (en) 2015-04-15 2016-10-20 University Of Massachusetts Compositions and methods for xi chromosome reactivation
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
AU2016293834A1 (en) 2015-07-10 2018-02-01 Asociación Centro de Investigación Cooperativa en Biociencias- CIC bioGUNE MCJ inhibitors for use in treating drug-induced diseases and conditions
WO2017024114A1 (en) 2015-08-06 2017-02-09 President And Fellows Of Harvard College Improved microbe-binding molecules and uses thereof
AU2016308694A1 (en) 2015-08-20 2018-02-22 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods and compositions to treat liver diseases and conditions
US11819554B2 (en) 2015-09-17 2023-11-21 University Of Massachusetts Compositions and methods for modulating FMR1 expression
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
PT3206672T (pt) 2015-10-27 2018-06-20 Eupraxia Pharmaceuticals Inc Formulações de libertação prolongada de anestésicos locais
EP3370703A4 (en) * 2015-11-06 2019-06-19 Gemphire Therapeutics Inc. GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES
WO2017143061A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CN108882722A (zh) * 2016-02-17 2018-11-23 科尔-詹森股份有限公司 食用油中的按时释放维生素和矿物质
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
CN116333140A (zh) 2016-04-08 2023-06-27 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体及其用途
EP3454891A4 (en) 2016-05-10 2019-12-25 The Regents of The University of Michigan EMULSION ADJUVANS FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION
TWI754643B (zh) 2016-05-16 2022-02-11 美商因塔希亞治療公司 升糖素受體選擇性多肽和彼之使用方法
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
CN109475510B (zh) * 2016-07-17 2023-03-10 Mapi医药公司 普瑞巴林的延长释放剂型
CR20190037A (es) 2016-07-26 2019-05-16 Bayer Animal Health Gmbh Aumento de la fertilidad en especies bovinas
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
CA3033973A1 (en) * 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release of fat-soluble actives
KR102613430B1 (ko) 2016-10-19 2023-12-18 더 스크립스 리서치 인스티튜트 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
EP3535588A4 (en) 2016-11-07 2020-09-16 University of Massachusetts THERAPEUTIC TARGET MOLECULES FOR FACIO-CAPULOHUMERAL MUSCLE DYSTROPHY
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US10786471B2 (en) 2017-02-06 2020-09-29 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
US10278930B2 (en) 2017-03-16 2019-05-07 The Procter & Gamble Company Method for relieving sinus congestion
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
US11225512B2 (en) 2017-04-27 2022-01-18 University Of New Hampshire Compositions and methods for ceramide-elevating therapeutic strategies
JP2020526537A (ja) 2017-07-14 2020-08-31 ユニバーシティ オブ マサチューセッツ 炎症を処置するための方法および組成物
JP2020533338A (ja) 2017-09-07 2020-11-19 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ ワクチン分子
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
RU2020135495A (ru) 2018-03-28 2022-04-29 Гербалайф Интернэшнл Оф Америка, Инк. Ацетилирование полисахаридов
IL277680B2 (en) 2018-04-09 2025-08-01 Checkmate Pharmaceuticals Inc Packaging oligonucleotides into virus-like particles
SG11202010347XA (en) 2018-04-19 2020-11-27 Tvardi Therapeutics Inc Stat3 inhibitors
WO2019241430A2 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
US12252556B2 (en) 2018-08-22 2025-03-18 Bacainn Biotherapeutics, Ltd. Cyclosporine compositions and methods of use
CN112912497B (zh) 2018-10-19 2024-01-12 德克萨斯州大学系统董事会 工程化长散在元件(line)转座子及其使用方法
KR20210072013A (ko) * 2018-11-02 2021-06-16 (주)셀트리온 비후성 심근증 치료용 약학 조성물
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN113660934A (zh) 2018-11-21 2021-11-16 特默罗制药股份有限公司 罗非昔布的纯化形式、制备方法和用途
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
CA3133629A1 (en) 2019-03-21 2020-09-24 Mitotherapeutix Llc Multivalent ligand clusters for targeted delivery of therapeutic agents
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
AU2020328507A1 (en) 2019-08-12 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
KR20220079880A (ko) 2019-10-07 2022-06-14 디.이. 쇼우 리서치, 엘엘씨 Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴메틸렌 헤테로시클릭 화합물
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
EP4107267A1 (en) 2020-02-21 2022-12-28 Mitotherapeutix LLC Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj)
JP7739334B2 (ja) 2020-05-08 2025-09-16 ジョージアミューン・インコーポレイテッド Ａｋｔ３モジュレーター
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
EP4059498A1 (en) 2021-03-16 2022-09-21 Centre Hospitalier Universitaire Vaudois (CHUV) Methods and compositions for treating conditions associated with hypermineralization
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
PH12023553237A1 (en) 2021-05-28 2024-04-29 De Shaw Res Llc Spiroindolinone compounds as kv1.3 potassium shaker channel blockers
EP4346783A1 (en) 2021-05-28 2024-04-10 MediciNova, Inc. Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
KR20240032010A (ko) 2021-06-09 2024-03-08 더 스크립스 리서치 인스티튜트 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
KR20240103025A (ko) 2021-11-16 2024-07-03 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
TW202329987A (zh) 2021-11-29 2023-08-01 大陸商上海舶望製藥有限公司 用於抑制乙型肝炎病毒（hbv）蛋白表達的組合物和方法
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
TW202400647A (zh) 2022-04-29 2024-01-01 美商普瑞諾生物科技公司 用於治療嗜酸性球驅動之疾病及病症的方法及組成物
JP2025527492A (ja) 2022-08-18 2025-08-22 エランコ・ユーエス・インコーポレイテッド 肥育素牛の発育成績を改善する方法
WO2024094526A1 (en) 2022-11-02 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) 6-diazo-5-oxo-l-norleucine prodrugs
CR20250257A (es) 2022-12-02 2025-08-28 Shanghai Argo Biopharmaceutical Co Ltd Análogos de ácidos nucleicos bicíclicos abásicos y compuestos oligoméricos preparados a partir de estos
WO2024173418A1 (en) 2023-02-16 2024-08-22 Infinitum Health, Llc Methods of inhibiting cancer growth and inhibiting viral infections
AU2024244071A1 (en) 2023-04-06 2025-10-30 Shanghai Argo Biopharmaceutical Co., Ltd. Nucleoside analog for 5'-phosphonate modification and oligonucleotide prepared therefrom
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
TW202521512A (zh) 2023-07-31 2025-06-01 美商美國禮來大藥廠 Kv1.3鉀shaker通道阻斷劑之固體形式及其使用方法
WO2025111679A1 (pt) * 2023-11-30 2025-06-05 Prati, Donaduzzi & Cia Ltda Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral
WO2025165367A1 (en) 2024-02-02 2025-08-07 Tris Pharma, Inc. Liquid clonidine extended release composition
WO2025208003A1 (en) * 2024-03-29 2025-10-02 Sen-Jam Pharmaceutical Inc. Pharmaceutical formulations and manufacturing processes
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases
WO2025257173A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2025257171A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2025257176A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) * 1962-12-19
CH434571A (de) * 1966-07-05 1967-04-30 Chemical And Pharmaceutical Pa Verfahren zur Herstellung von Antibiotika mit verlängerter therapeutischer Wirkung
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
US3623997A (en) * 1966-06-06 1971-11-30 Ncr Co Wall-sealing treatment for minute capsules and minute capsules having walls of sealed polymeric material
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
NL131321C (es) * 1967-05-05
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
IT1115596B (it) * 1978-03-13 1986-02-03 Bayer Italia Spa Metodo per la preparazione di microgranuli gastoresistenti ed enterosolubili di sostanze farmaceutiche,in particolare di sostanze proteiche e microgranuli preparati con detto metodo
JPS5545601A (en) * 1978-09-26 1980-03-31 Toyo Jozo Co Ltd Long-acting cephalexin and its preparation
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
DE2950977A1 (de) * 1978-12-22 1980-07-10 Donald E Panoz Neue galenische zubereitungsform fuer die orale verabreichung von medikamenten mit programmierter besetzung, sowie verfahren zu ihrer herstellung
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
ATE10582T1 (de) * 1981-01-22 1984-12-15 Capsugel A.G. Verfahren zur herstellung pharmazeutischer, darmloeslicher kapseln.
GB2098867B (en) * 1981-05-21 1984-10-24 Wyeth John & Brother Ltd Sustained release pharmaceutical composition
JPS5826816A (ja) * 1981-08-11 1983-02-17 Teisan Seiyaku Kk 球形顆粒からなる持続性複合顆粒剤
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
IE53703B1 (en) * 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US4501018A (en) * 1983-07-05 1985-02-19 Motorola, Inc. Simplex transceiver employing a common piezoelectric element for transmitting and receiving
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
DE3333639A1 (de) * 1983-09-17 1985-03-28 Dynamit Nobel Ag Zubereitung von nitroestern fuer die koronartherapie
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
GB2159715B (en) * 1984-06-04 1988-05-05 Sterwin Ag Pharmaceutical composition in sustained release unit dose form and process for its preparation
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
JPH0780754B2 (ja) * 1986-08-06 1995-08-30 エーザイ株式会社 多顆粒型持続性錠剤
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
GB8702411D0 (en) * 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
DK173505B1 (da) * 1987-02-20 2001-01-15 Pharmatec Internat S R L Fremgangsmåde til fremstilling af en diltiazempellet med langsom afgivelse og anvendelse af således fremstillede pelleter t
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same

Also Published As

Publication number Publication date
US5133974A (en) 1992-07-28
ATE128863T1 (de) 1995-10-15
US5445829A (en) 1995-08-29
CA2016039A1 (en) 1990-11-05
DE69022876T2 (de) 1996-05-02
EP0396425A2 (en) 1990-11-07
EP0396425B1 (en) 1995-10-11
EP0396425A3 (en) 1992-11-19
CA2016039C (en) 2001-07-17
DE69022876T3 (de) 1999-06-17
AU635021B2 (en) 1993-03-11
EP0396425B2 (en) 1998-12-30
AU5470390A (en) 1990-11-08
ES2080796T5 (es) 1999-05-16
DE69022876D1 (de) 1995-11-16

Similar Documents

Publication Publication Date Title
ES2080796T3 (es) Formulaciones de productos farmaceuticos de liberacion prolongada.
AU4999890A (en) Pharmaceutical composition providing the sustained release of valproic acid
FR2683146B1 (fr) Compositions pharmaceutiques a liberation reglee de la substance medicamenteuse.
FR2624732B1 (fr) Formulation pharmaceutique a liberation prolongee
DK205889A (da) Vandbaseret farmaceutisk overtraeksmateriale til doseringsformer
AU1834392A (en) Matrix tablet permitting the sustained release of indapamide after oral administration
AU6770490A (en) Solid pharmaceutical compositions containing cimetidine
PT86819A (pt) Process for the preparation of novel insulin derivatives and of pharmaceutical compositions containing the same
DE69015842D1 (de) Nicotinsäurederivate und diese enthaltende pharmazeutische Zusammensetzungen.
AU6314790A (en) Oral pharmaceutical composition for acid sensitive proteinaceous agents
DE19975037I2 (de) 3H-Imidazo-5,1-d-1,2,3,5-tetrazin-4-on-Derivate Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
IT1144911B (it) Composizione farmaceutica a rilascio controllato contenente ibuprofen
FI902433A7 (fi) Menetelmä jauhemaisen polydekstroosin valmistamiseksi, joka on olennaisesti vapaa hapoista ja sitä sisältäviä koostumuksia
EP0448091A3 (en) Pharmaceutical composition containing slightly water-soluble drug
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
DE3887068D1 (de) 2,2-Dimethylchromenderivate, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
NO884005L (no) Fluorerte derivater av aminosyrer saerlig for bruk som overflateaktive midler.
DE69214333D1 (de) Arzneizubereitung mit hohem Gehalt an Ibuprofenlysinat
AU1888488A (en) Substituted benzimidazoles, a process for the preparation thereof, pharmaceutical formulations containing them, and theuse thereof
PT88634A (pt) A process for the preparation of catechol carboxylic acid derivatives and of pharmaceutical compositions containing the same
PT87679A (pt) A process for the preparation of 2-methoxymethyl-penem derivatives and of pharmaceutical compositions containing the same
IT1228130B (it) Derivati dell'1,1,2-trifenilpropano e dell'1,1,2-trifenilpropene, procedimento per la loro preparazione e composizioni farmaceutiche contenenti i composti
AU3041789A (en) Pharmaceutical formulations with controlled drug release
PT86933A (pt) Process for the preparation pf optically active oxo-isoindolinyul derivatives and of pharmaceutical compositions containing the same
GB2025224B (en) Pharmaceutical compositions comprising trimethoprim and n ethyl pyridone 3 carboxylic acid derivatives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 396425

Country of ref document: ES